These Could Be Jazz Pharmaceuticals’ Long-Term Growth Drivers

In June, the FDA accepted Jazz Pharmaceuticals’ (JAZZ) supplemental new drug application (or sNDA) for the label expansion of Xyrem. Jazz Pharmaceuticals filed an sNDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric narcolepsy patients. Jazz Pharmaceuticals’ sNDA was supported by data from the Phase 2/3 EXPRESS trial, which was conducted on pediatric patients between seven and 17 years old with narcolepsy.